Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Companion animal trials to help human patients
Professor Wouda
The study focuses on dogs because of the similarities between their cancers and human cancers.

Researchers test innovative treatment options 

Clinical trials to treat cancers in cats, dogs, and other companion animals are underway at Kansas State University.

Raelene Wouda, assistant professor of clinical sciences, is offering groundbreaking new treatments to pet owners at a reduced cost.

In addition to improved diagnostic testing and monitoring approaches, the trials include innovative treatment options including combination chemotherapy, t-cell transfer and nanoparticle drug formulations.


As well as improving outcomes for veterinary patients, Wouda hopes the research will provide important information for how the disease can be better diagnosed, monitored and treated in humans.


“For many pet owners, cancer is a terminal diagnosis for they beloved family member,” Wouda said. “These studies provide an opportunity to trial a cutting-edge therapy for their pets at a reasonable price.”

“Moreover, owners participating in these clinical trials take comfort and are pleased to know that they are helping to achieve better treatments and outcomes for pets that may be diagnosed with cancer in the future.”

Professor Wouda’s research, published in the journal Veterinary Comparative Oncology, has been described as a ‘crucial step’ towards a long-term cure for many cancers.

The study focuses on dogs because of the similarities between their cancers and human cancers, like melanoma, lung cancer and osteosarcoma.


Dogs also live with us and are exposed to the same environmental factors, explained Wouda. Furthermore, because dogs age faster than humans, their disease progresses faster, which is a practical advantage for evaluating the efficacy and clinical benefits of new treatments.

"We get clinical answers more quickly in dogs," Wouda said. "The benefit of a particular therapy becomes evident in dogs more rapidly compared to people, and because of this we can preserve research and development finances, but more importantly, we save valuable time and resources."

Professor Wouda will work with graduate students, oncology technicians and referral veterinary surgeons to conduct the clinical trials.

She will also collaborate with human medical researchers to discuss how the research can be best applied to the field of human oncology.

Image (C) Kansas State University

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
UK's BSE risk status downgraded

The WOAH has downgraded the UK's international risk status for BSE to 'negligible'.

Defra says that the UK's improved risk status recognises the reputation for having the highest standards for biosecurity. It adds that it demonstrates decades of rigorous animal control.

Outbreaks of Bovine Spongiform Encephalopathy, also known as mad cow disease, have previously resulted in bans on Britain's beef exports.

The UK's new status could lead to expanded trade and better confidence in British beef.

Christine Middlemiss, the UK's chief veterinary officer, said: "WOAH's recognition of the UK as negligible risk for BSE is a significant milestone and is a testament to the UK's strong biosecurity measures and the hard work and vigilance of farmers and livestock keepers across the country who have all played their part in managing the spread of this disease.